GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Common Stock

Labiana Health (XMAD:LAB) Common Stock : €0.72 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Common Stock?

Labiana Health's quarterly common stock stayed the same from Jun. 2023 (€0.72 Mil) to Dec. 2023 (€0.72 Mil) and stayed the same from Dec. 2023 (€0.72 Mil) to Jun. 2024 (€0.72 Mil).

Labiana Health's annual common stock increased from Dec. 2021 (€0.62 Mil) to Dec. 2022 (€0.72 Mil) but then stayed the same from Dec. 2022 (€0.72 Mil) to Dec. 2023 (€0.72 Mil).


Labiana Health Common Stock Historical Data

The historical data trend for Labiana Health's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Common Stock Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Common Stock
0.62 0.62 0.72 0.72

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial 0.72 0.72 0.72 0.72 0.72

Labiana Health Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Labiana Health Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.